A Contract Research and
                  Development Company
Chemistry Banner

Our Team

Anu Mahadevan, Ph.D.

Chief Executive Officer

Anu Mahadevan

Dr. Mahadevan received her Ph.D. in Organic Chemistry in 1994 from Purdue University under the supervision of Professor Fuchs. She then spent a postdoctoral period with Professor Holton at Florida State University. In 1997 she joined Organix as a postdoctoral researcher where she rose to the position of Vice President and member of the Board of Directors. Dr. Mahadevan supervises several proprietary projects. Her non-proprietary work, funded by the National Institutes of Health, has focused on the design and synthesis of compounds in the cannabinoid field. Dr. Mahadevan’s published work includes over 39 publications and 6 patents. (more...)

Paul Blundell, Ph.D.

President

Paul Blundell

Dr. Blundell received his Ph.D. in Organic Chemistry in 1991 from the University of Stirling, Scotland. This research was conducted as a Schering Scholar at Texas A & M University under the supervision of Nobel Laureate Sir Derek H. R. Barton. Following his Ph.D., he spent a postdoctoral year with Schering-Plough working with Dr. Ashit Ganguly in the azole antifungal field. In 1993 he joined Organix where he rose to the position of Vice President and member of the Board of Directors. Dr. Blundell supervises various proprietary projects at Organix. His non-proprietary research under the supervision of Dr. Meltzer and funded by the National Institutes of Health has focused on the design and synthesis of monoamine uptake inhibitors with a view to discovery of cocaine pharmacotherapies and brain imaging agents. Dr. Blundell’s published work includes over 24 publications and 12 patents. Dr. Blundell’s responsibilities include management of information technology (IT). (more...)

Howard P. Sard, Ph.D.

Vice President & Co-founder

Howard P. Sard

Dr. Sard received his Ph.D. in Organic Chemistry in 1982 from the Massachusetts Institute of Technology working with Professor Rick Danheiser. In 1982 he joined SISA, Cambridge, MA, where he worked as a postdoctoral researcher, and later as a Group Leader. In 1986 he co-founded Organix where he is currently Vice President and a member of the Board of Directors. Dr. Sard supervises proprietary projects at Organix. His non-proprietary work, funded by the National Institutes of Health, has focused on the design and synthesis of selective serotonin receptor compounds useful as treatments for obesity and CNS-related diseases. Dr. Sard is responsible for monitoring all work with controlled substances and all interactions with the US Drug Enforcement Agency. He is the company Safety Officer. Dr. Sard has published 18 papers and 6 patents in areas including aliphatics, especially small carbocycles, heterocyclic compounds, nucleosides, cannabinoids, tryptamines, and new synthetic methods. (more...)

Back to Top

Research at Organix